Login to Your Account

Portola's factor Xa inhibitor antidote puts brakes on bleeding

By Michael Fitzhugh
Staff Writer

Wednesday, October 1, 2014
Portola Pharmaceuticals Inc.'s shares (NASDAQ:PTLA) rose 16 percent higher Wednesday, climbing $4.04 to close at $29.32, after the company shared top-line data from the first of two planned phase III studies showing that andexanet alfa, its universal factor Xa inhibitor antidote, met its primary and secondary endpoints.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription